



Updates: Office of Infectious Disease and HIV/AIDS Policy



Office of Infectious Disease and HIV/AIDS Policy (OIDP)

- Provides strategic leadership and management among federal agencies and stakeholders to reduce burden of infectious diseases
- Ending the HIV Epidemic; Minority HIV/AIDS Fund; Ready, Set, PrEP
- National Strategic Plans – HIV, Vaccine, STI, Viral Hepatitis, Vectorborne Disease
- Federal Interagency Workgroups
- Federal Advisory Committees
 - Presidential Advisory Council on HIV/AIDS
 - National Vaccine Advisory Committee
 - Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
 - Advisory Committee on Blood and Tissue Safety and Availability,
 - Tick-Borne Disease Working Group



OIDP Updates

- **“Catch Up to Get Ahead” Initiative**
 - Redoubles catch-up vaccination efforts for children during August “National Immunization Awareness Month”
- **Public Readiness and Emergency Preparedness (PREP) Act**
 - Authorizes pharmacists to administer vaccines to children age 3–18 years during emergency declaration
 - Extends immunity to claims for loss per 42 U.S.C. § 247d-6d(a)(1)
- **National Vaccine Advisory Committee**
 - Last meeting June 9, next meeting Sep 23–24
 - To reconvene Vaccine Confidence and Immunization Equity Subcommittees
- **National Vaccine Plan**
 - Updates 2010 plan, 5-year horizon
 - Incorporates expert and stakeholder interviews, public comments, interagency reviews
 - Plan for release Dec 2020



Healthy People 2030


- **Launched Aug 19, 2020**
- **365 core, 144 developmental objectives**
- **Core objectives**
 - **Reduce children with no vaccines by age 2y**
 - **Maintain 1 dose MMR by age 2y**
 - **Maintain 2 doses MMR by kindergarten**
 - **Increase 4 doses DTaP by age 2y**
 - **Increase adolescents who get HPV vaccines**
 - **Increase people who get flu vaccine every year (leading health indicator)**
- **Developmental objectives**
 - **Increase pregnant women who get Tdap**
 - **Increase people with vaccination records in vaccine registries**
 - **Increase adults age $\geq 19y$ who get recommended vaccinations**



Vaccine Safety Report

- **Purpose**
 - **Assess evidence on safety of routinely recommended vaccines with review of adverse events reported in literature since last published report in July 2014**
- **Evidence review of vaccine safety**
 - **Clinical trials, post-marketing surveillance, nationwide reporting systems**
 - **Builds on prior report using PubMed, EMBASE, NINAHL, CENTRAL, Web of Science, Scopus, TOXLINE**
 - **New formulations, new indications**
 - **Types and severity with individual and combination vaccines**
 - **Transient vs. permanent health risks, frequency and likelihood of adverse events**
 - **Associated factors (e.g., age, sex, race/ethnicity, comorbidities)**
- **Scope of review**
 - **FDA-licensed vaccines on CDC-recommended immunization schedules**
 - **Children, adults, pregnant women**





Vaccine Safety Report – Pending Actions

- Draft report and internal review
- Report presentation and peer-review
- Submit for HHS clearance
- Distribution of finalized report – December 2020





**Office of Infectious Disease and HIV/AIDS Policy
Office of the Assistant Secretary for Health
Department of Health and Human Services**

**WWW.VACCINES.GOV
WWW.HHS.GOV/VACCINES
WWW.HHS.GOV/OIDP
[@HHSVACCINES](https://twitter.com/HHSVACCINES)**